Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CCR2 | P41597 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274786 | 0.78 | CCR2 (0.50) | TDP1CCR2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL3468425 | 0.76 | TDP1 (0.46) | TDP1CCR2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL11050586 | 0.74 | TDP1 (0.43) | TDP1CCR2ALDH1A1L3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL11049903 | 0.74 | TDP1 (0.43) | TDP1CCR2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL11050566 | 0.74 | TDP1 (0.43) | TDP1CCR2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL1168696 | 0.73 | CTRC (0.33) | TDP1ALDH1A1HSD17B10 | |
| SCHEMBL13908191 | 0.73 | TDP1 (0.42) | TDP1CCR2ALDH1A1L3MBTL1MAPT | |
| Cimlanod SCHEMBL15878610 | 0.71 | CA1 (0.45) | TDP1CCR2ALDH1A1L3MBTL1POLB | |
| SCHEMBL18007541 | 0.71 | ALDH1A1 (0.34) | ALDH1A1MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL9353697 | 0.70 | TLR9 (0.38) | TDP1CCR2ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| US-12186301-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| US-20240066002-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | CARDIOXYL PHARMACEUTICALS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| EP-1369419-B1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO (JP) | 2007-05-23 | — | — | EP | disclosed |
| CN-1294126-C | N-phenyl-arylsulfonamide compound, drug comprising the compound as active ingredient, intermediate for the compound | ONO PHARMACENTICAL CO LTD (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | disclosed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-4430355-A | ARTIFICIAL SWEETENER | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-02-07 | — | — | US | disclosed |
| US-4233333-A | 4,5-Dimethyl-thieno[3,2-d]isothiazolo-3(2H)-one-1,1-dioxides, compositions, and methods of use as a sweetener | BOEHRINGER INGELHEIM GMBH (DE) | 1980-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | PTGER1, PTGER2, PTGES | TDP1 3545/4885CCR2 980/4885ALDH1A1 1732/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | TDP1 1954/4885CCR2 1246/4885ALDH1A1 3407/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | TDP1 2453/4885CCR2 2062/4885ALDH1A1 3558/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | TDP1 1235/4885CCR2 1975/4885ALDH1A1 2556/4885 |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | PTGER1, PTGER2, PTGES | TDP1 3189/4885CCR2 879/4885ALDH1A1 1222/4885 |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | TDP1 1666/4885CCR2 3369/4885ALDH1A1 924/4885 |
| US-12186301-B2 | Nitroxyl donors with improved therapeutic index | TNNI3, TNNT2, TNNC1 | TDP1 591/4885CCR2 3676/4885ALDH1A1 1005/4885 |
| US-20240066002-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | TNNI3, TNNT2, TNNC1 | TDP1 591/4885CCR2 3676/4885ALDH1A1 1005/4885 |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | TDP1 3390/4885CCR2 1215/4885ALDH1A1 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.